Kevin McCulloch

Kevin McCulloch discloses dealings in Xeris Biopharma Holdings, Inc. to SEC (Form 4). Over a trading history stretching from 1 August 2024 to 1 October 2026, the count stands at 22 filings.

In open-market terms, that means 1 purchase worth €94k on one side and 5 sales worth €661k on the other. Sales outweigh purchases by €566k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 13 share grants and 2 option exercises. So far in 2026, the count stands at no purchases and 5 sales.

On 2 October 2026 came the latest disclosure, an open-market sale for €124k in Xeris Biopharma Holdings, Inc. The latest purchase dates back some time: it was published 495 days ago, on 16 June 2025. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.